Literature DB >> 23163951

Symptomatology of autism spectrum disorder in a population with neurofibromatosis type 1.

Karin S Walsh1, Jorge I Vélez, Peter G Kardel, Daniel M Imas, Maximilian Muenke, Roger J Packer, Francisco X Castellanos, Maria T Acosta.   

Abstract

AIM: Difficulties in neurocognition and social interaction are the most prominent causes of morbidity and long-term disability in children with neurofibromatosis type 1 (NF1). Symptoms of attention-deficit-hyperactivity disorder (ADHD) have also been extensively recognized in NF1. However, systematic evaluation of symptoms of autism spectrum disorder (ASD) in children with NF1 has been limited.
METHOD: We present a retrospective, cross-sectional study of the prevalence of symptoms of ASD and ADHD and their relationship in a consecutive series of 66 patients from our NF1 clinic. The Social Responsiveness Scale and the Vanderbilt ADHD Diagnostic Parent Rating Scale were used to assess symptoms of ASD and ADHD.
RESULTS: Sixty-six participants (42 males, 24 females) were included in this study. Mean age at assessment was 10 years 11 months (SD 5 y 4 mo). Forty percent of our NF1 sample had raised symptom levels reaching clinical significance on the Social Responsiveness Scale (T ≥ 60), and 14% reached levels consistent with those seen in children with ASDs (T ≥ 75). These raised levels were not explained by NF1 disease severity or externalizing/internalizing behavioral disorders. There was a statistically significant relationship between symptoms of ADHD and ASD (χ(2) =9.11, df=1, p=0.003, φ=0.56). Particularly salient were the relationships between attention and hyperactivity deficits, with impairments in social awareness and social motivation.
INTERPRETATION: We found that symptoms of ASD in our NF1 population were raised, consistent with previous reports. Further characterization of the specific ASD symptoms and their impact on daily function is fundamental to the development and implementation of effective interventions in this population, which will probably include a combination of medical and behavioral approaches. © The Authors. Developmental Medicine & Child Neurology
© 2012 Mac Keith Press.

Entities:  

Mesh:

Year:  2012        PMID: 23163951     DOI: 10.1111/dmcn.12038

Source DB:  PubMed          Journal:  Dev Med Child Neurol        ISSN: 0012-1622            Impact factor:   5.449


  44 in total

Review 1.  An update on the central nervous system manifestations of neurofibromatosis type 1.

Authors:  J Stephen Nix; Jaishri Blakeley; Fausto J Rodriguez
Journal:  Acta Neuropathol       Date:  2019-04-08       Impact factor: 17.088

Review 2.  Using genetic findings in autism for the development of new pharmaceutical compounds.

Authors:  Jacob A S Vorstman; Will Spooren; Antonio M Persico; David A Collier; Stefan Aigner; Ravi Jagasia; Jeffrey C Glennon; Jan K Buitelaar
Journal:  Psychopharmacology (Berl)       Date:  2013-11-30       Impact factor: 4.530

3.  RASopathies are associated with a distinct personality profile.

Authors:  Varoona Bizaoui; Jessica Gage; Rita Brar; Katherine A Rauen; Lauren A Weiss
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2018-04-16       Impact factor: 3.568

4.  Social Function and Autism Spectrum Disorder in Children and Adults with Neurofibromatosis Type 1: a Systematic Review and Meta-Analysis.

Authors:  Anita K Chisholm; Vicki A Anderson; Natalie A Pride; Stephanie Malarbi; Kathryn N North; Jonathan M Payne
Journal:  Neuropsychol Rev       Date:  2018-08-11       Impact factor: 7.444

5.  Neurofibromatosis Type 1 Implicates Ras Pathways in the Genetic Architecture of Neurodevelopmental Disorders.

Authors:  Jessica A Kaczorowski; Taylor F Smith; Amanda M Shrewsbury; Leah R Thomas; Valerie S Knopik; Maria T Acosta
Journal:  Behav Genet       Date:  2020-02-05       Impact factor: 2.805

6.  Distribution and Within-Family Specificity of Quantitative Autistic Traits in Patients with Neurofibromatosis Type I.

Authors:  John N Constantino; Yi Zhang; Kieran Holzhauer; Sayli Sant; Kyna Long; Alicia Vallorani; Leena Malik; David H Gutmann
Journal:  J Pediatr       Date:  2015-06-04       Impact factor: 4.406

7.  Characterization of early communicative behavior in mouse models of neurofibromatosis type 1.

Authors:  Susan E Maloney; Krystal C Chandler; Corina Anastasaki; Michael A Rieger; David H Gutmann; Joseph D Dougherty
Journal:  Autism Res       Date:  2017-08-26       Impact factor: 5.216

8.  CTF meeting 2012: Translation of the basic understanding of the biology and genetics of NF1, NF2, and schwannomatosis toward the development of effective therapies.

Authors:  Brigitte C Widemann; Maria T Acosta; Sylvia Ammoun; Allan J Belzberg; Andre Bernards; Jaishri Blakeley; Antony Bretscher; Karen Cichowski; D Wade Clapp; Eva Dombi; Gareth D Evans; Rosalie Ferner; Cristina Fernandez-Valle; Michael J Fisher; Marco Giovannini; David H Gutmann; C Oliver Hanemann; Robert Hennigan; Susan Huson; David Ingram; Joe Kissil; Bruce R Korf; Eric Legius; Roger J Packer; Andrea I McClatchey; Frank McCormick; Kathryn North; Minja Pehrsson; Scott R Plotkin; Vijaya Ramesh; Nancy Ratner; Susann Schirmer; Larry Sherman; Elizabeth Schorry; David Stevenson; Douglas R Stewart; Nicole Ullrich; Annette C Bakker; Helen Morrison
Journal:  Am J Med Genet A       Date:  2014-01-17       Impact factor: 2.802

9.  The genetic and neuroanatomical basis of social dysfunction: lessons from neurofibromatosis type 1.

Authors:  Natalie A Pride; Mayuresh S Korgaonkar; Belinda Barton; Jonathan M Payne; Steve Vucic; Kathryn N North
Journal:  Hum Brain Mapp       Date:  2013-07-24       Impact factor: 5.038

10.  Brief Report: The Prevalence of Neurofibromatosis Type 1 among Children with Autism Spectrum Disorder Identified by the Autism and Developmental Disabilities Monitoring Network.

Authors:  Deborah A Bilder; Amanda V Bakian; David A Stevenson; Paul S Carbone; Christopher Cunniff; Alyson B Goodman; William M McMahon; Nicole P Fisher; David Viskochil
Journal:  J Autism Dev Disord       Date:  2016-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.